Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Beyond Air Inc (XAIR)

Beyond Air Inc (XAIR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,371
  • Shares Outstanding, K 10,529
  • Annual Sales, $ 3,710 K
  • Annual Income, $ -46,630 K
  • EBIT $ -22 M
  • EBITDA $ -40 M
  • 60-Month Beta 0.39
  • Price/Sales 3.07
  • Price/Cash Flow N/A
  • Price/Book 1.04

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -3.00
  • Growth Rate Est. (year over year) +33,400.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9515 +14.56%
on 02/12/26
2.2600 -51.77%
on 01/20/26
-0.6100 (-35.88%)
since 01/16/26
3-Month
0.6733 +61.89%
on 12/29/25
2.6600 -59.02%
on 01/13/26
-0.2600 (-19.26%)
since 11/19/25
52-Week
0.6733 +61.89%
on 12/29/25
7.6000 -85.66%
on 02/20/25
-6.5000 (-85.64%)
since 02/19/25

Most Recent Stories

More News
Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

Increased revenue by 105% year-over-year (YoY) to $2.2 million in fiscal Q3 Maintain fiscal year 2026 revenue guidance of $8-10 million $22.3 million pro forma cash, cash equivalents, restricted...

XAIR : 1.0900 (+0.93%)
Beyond Cancer Abstract Featuring Phase 1 Data on Intratumoral Ultra-High Concentration Nitric Oxide (UNO) in Solid Tumor Metastases to be Presented at the AACR Annual Meeting 2026

GARDEN CITY, N.Y., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid...

XAIR : 1.0900 (+0.93%)
Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences

GARDEN CITY, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...

XAIR : 1.0900 (+0.93%)
Beyond Air Schedules Third Fiscal Quarter 2026 Financial Results Conference Call and Webcast

GARDEN CITY, N.Y., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...

XAIR : 1.0900 (+0.93%)
Beyond Air Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

GARDEN CITY, N.Y., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...

XAIR : 1.0900 (+0.93%)
XTL Biopharmaceuticals Acquires 85% of Beyond Air’s Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership

Unmatched scientific firepower: Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcher Critical unmet need: 1 in 31 U.S. children now affected, zero FDA-approved disease-modifying...

XAIR : 1.0900 (+0.93%)
XTLB : 0.8893 (-0.48%)
Beyond Air® Appoints Dan Moorhead as Chief Financial Officer

GARDEN CITY, N.Y., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...

XAIR : 1.0900 (+0.93%)
Beyond Air® Signs New International LungFit PH® Distribution Agreements, Most Notably in Germany and Brazil

GARDEN CITY, N.Y., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...

XAIR : 1.0900 (+0.93%)
Beyond Air® Announces Transition of Chief Financial Officer

GARDEN CITY, N.Y., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...

XAIR : 1.0900 (+0.93%)
Beyond Air® Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update

Increased revenue by 128% year over year (YoY) to $1.8 million Appointed Beyond Air Board member Bob Goodman as Interim Chief Commercial Officer Raised $12.0 million in debt financing; proforma...

XAIR : 1.0900 (+0.93%)

Business Summary

Beyond Air Inc. is a clinical-stage medical device and biopharmaceutical company. It is engaged in developing a Nitric Oxide Generator and Delivery System. The company's principal product is AirNOvent which is in clinical stage. Beyond Air Inc., formerly known as AIT Therapeutics Inc., is based in Garden...

See More

Key Turning Points

3rd Resistance Point 1.1833
2nd Resistance Point 1.1367
1st Resistance Point 1.1133
Last Price 1.0900
1st Support Level 1.0433
2nd Support Level 0.9967
3rd Support Level 0.9733

See More

52-Week High 7.6000
Fibonacci 61.8% 4.9540
Fibonacci 50% 4.1367
Fibonacci 38.2% 3.3193
Last Price 1.0900
52-Week Low 0.6733

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar